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FREQUENCY AND RISK FACTORS OF GOUT FLARES IN A LARGE 
POPULATION-BASED COHORT OF INCIDENT GOUT
Rothenbacher D1, Primatesta P1, Ferreira A1, Cea Soriano L2, Garcia LA2
1Novartis Pharma AG, Basel, Switzerland; 2CEIFE—Centro Español de Investigación 
Farmacoepidemiológica, Madrid, Spain
OBJECTIVES: To describe the frequency and risk factors of gout ﬂ ares in a large 
cohort of incident gout. METHODS: A cohort study was conducted in an UK general 
practice database (The Health Improvement network (THIN)) in the study period 
January 2000 through December 2008. All patients aged 20–89 years diagnosed with 
incident gout between the years 2000–2007 were included; their history of ﬂ ares 
recorded over time. We studied the association between several factors and the number 
of ﬂ ares. a Cox proportional hazards model was used to identify determinants of risk 
of ﬁ rst ﬂ are. RESULTS: The overall incidence rate of gout was 2.68 (95% conﬁ dence 
interval (CI) 2.65–2.72) per 1,000 person-years, and 23,857 incident gout patients 
(mean age 61.9 years) were included in this study. The incidence rate of a ﬁ rst ﬂ are 
was 13.7 (95% CI 13.4–14.0) per 100 person-years. The proportion of patients with 
at least one ﬂ are during the follow-up period (mean 3.8 years) was 36.9% (n = 8,806). 
Male gender, alcohol consumption and history of cardiometabolic diseases were posi-
tively associated with number of ﬂ ares (P < 0.001). The hazard ratio estimate of ﬁ rst 
ﬂ are associated with antecedents of renal failure disorders was 1.33 (CI 95% 1.20–
1.48), 1.41 (CI 95% 1.26–1.58) for drinking more than 42 alcohol units per week, 
and 1.22 (CI 95% 1.14–1.30) for a body mass index greater than 30 kg/m2. Also, a 
higher risk of a ﬁ rst ﬂ are was associated with a history of ischemic heart disease, and 
hypertension (HR: 1.12 (95% CI 1.06–1.19) and 1.15 (95% CI 1.10-1-20), respec-
tively). CONCLUSIONS: Gout ﬂ ares are the most common clinical manifestation in 
patients suffering from gout disease. Male sex, modiﬁ able life-style factors as well as 
comorbid conditions are important independent risk factors for ﬁ rst ﬂ are.
PMS16
EARLY MORTALITY RATE OF BILATERAL HIP FRACTURES OVER 60 IN 
HUNGARY
Sebestyen A1, Lipp S1, Boncz I2
1Baranya County Health Insurance Fund, Pécs, Hungary; 2University of Pécs, Pécs, Hungary
OBJECTIVES: The aim of the study is to analyze the early mortality rate after bilateral 
hip and femur fractures over 60 in Hungary. METHODS: In this retrospective study 
the data derive from the ﬁ nancial database of the National Health Insurance Fund of 
Hungary. For the analysis we used code S7200 of the International Classiﬁ cation of 
Diseases (ICD) tenth revision. The patients included into the study had femoral neck 
fracture and being discharged from the hospital after the primary treatment in 2000. 
The patients with polytrauma were excluded from the study. The follow up was 8 
years. The patients were categorized according to sex, age, fracture type, surgical 
methods, presence of accompanying diseases and day of hospital admission. We 
analyzed the early mortality rate within 30 days after treatment of bilateral hip and 
femur fracture. RESULTS: Altogether 347 patients were included into the study. The 
national average of mortality was 7.5%. We demonstrated the following early mortal-
ity rate according to risk factors: Sex: male: 13.2%, female: 6.5%. Age groups: 
60–69 y: 5.4%, 70–79 y: 5.9%, 80 y-: 8.9%. Type of fractures: femoral neck frac-
tures: 4.2%, pertrochanteric fractures: 15.5%, femur fractures: 5.9%. Surgical tech-
niques: arthroplasty: 3.1%, osteosynthesis: 7.8%. Accompanying diseases: yes: 8.1%, 
no: 2.6%. Day of hospital admission: weekday: 7.4%, weekend: 7.7%. CONCLU-
SIONS: The early mortality rate increased with the age of patients. In the analysis 
according to sex, type of fracture and presence of accompanying diseases we found 
higher mortality in male, in patient with pertrochanteric fracture and in patient with 
accompanying diseases. According to surgical intervention early mortality rate is 
higher in patient with osteosynthesis. Many other factors can inﬂ uence this mortality, 
which will be analyzed in our further studies. 
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PMS17
BUDGET IMPACT OF NEW RHBMP-2 FORMULATION IN PATIENTS 
UNDERGOING POSTEROLATERAL SPINAL FUSION PROCEDURES FOR 
DEGENERATIVE DISC DISEASE IN RANDOMIZED CONTROLLED TRIAL 
(RCT)
McInnis MM1, Olchanski N1, Kemner JE2, Goss T1
1Boston Healthcare Associates, Inc., Boston, MA, USA; 2Medtronic Spinal and Biologics, 
Memphis, TN, USA
OBJECTIVES: A new formulation of recombinant human bone morphogenetic 
protein-2 (rhBMP-2) on a Compression Resistant Matrix (CRM) evaluated in pos-
terolateral spinal fusion (PLF) procedures for degenerative disc disease (DDD) has the 
potential to improve clinical outcomes and decrease costs. The rhBMP-2/CRM pivotal 
study demonstrated signiﬁ cant improvement in spinal fusion rates compared to pro-
cedures using iliac crest bone graft (ICBG), (Dimar 2009). This study evaluated the 
likely budget impact of rhBMP-2/CRM on U.S. payer costs compared to ICBG pro-
cedures in PLF. METHODS: A budget impact model was developed to quantify clini-
cal and economic outcomes for patients with single-level symptomatic DDD and the 
U.S. payer costs of rhBMP-2/CRM in PLF procedures. The model results compare use 
of rhBMP-2/CRM to the use of ICBG in these procedures. Both study arms use pos-
terior supplemental ﬁ xation. The 24-month clinical data was derived from 463 
patients in the rhBMP-2/CRM pivotal study trial and included independent radio-
graphic assessment of fusion success rates, re-surgery rates, and complications rates 
(infections, bleeding, cardiovascular complications, GI complications). Payer costs and 
clinical practice data were derived from published sources and from the 2007 Medi-
care Inpatient Standard Analytic File and inﬂ ated to 2010 costs using the medical care 
component of the U.S. Consumer Price Index. RESULTS: The average 2-year costs 
per patient treated with ICBG were $53,740. Comparatively, treating patients with 
rhBMP-2/CRM is estimated to reduce average costs by 12% ($6,252) per patient. 
Cost reductions were primarily driven by a reduction in subsequent surgeries. Fusion 
rates at 2 years were greater in the rhBMP-2/CRM group compared to the ICBG group 
(96% vs. 89% at p = 0.014). CONCLUSIONS: This budget impact model based on 
RCT data demonstrates that the use of rhBMP-2/CRM in treatment of DDD patients 
undergoing PLF procedures is associated with substantial cost savings to payers when 
compared with traditional ICBG procedures.
PMS18
A BUDGET IMPACT MODEL FOR THE ECONOMIC ASSESSMENT OF 
TOCILIZUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS 
PATIENTS IN ITALY
Iannazzo S1, Zaniolo O1, Giuliani G2
1Adres srl, Torino, Italy; 2Roche S.p.A., Monza, Italy
OBJECTIVES: A Budget Impact Model (BIM) was developed to assess the impact on 
Italian National Health Service (NHS) expenditure caused by the use of tocilizumab 
(TOC) , monoclonal antibody approved by EMA in early 2009, as a ﬁ rst-line biologic 
treatment vs. traditional anti-TNFα therapies in the treatment of moderate to severe 
rheumatoid arthritis (RA) patients. METHODS: A Markov model was used to simu-
late the progression of a cohort of RA patients through three lines of biologic treat-
ments with anti-TNFα and TOC, palliative therapy and death. The horizon was 5 
years. The target population was deﬁ ned by the number of incident RA patients eli-
gible to ﬁ rst-line biologic treatment based on Italian epidemiological and market data. 
First-line TOC followed by a second- and a third-line anti-TNFα treatment was 
compared a more traditional strategy based on anti-TNFα cycling. Direct medical 
costs were considered: drug acquisition, administration and monitoring tests, accord-
ing to current prices and tariffs. To estimate the relative effectiveness of use of eco-
nomic resources, the average number of patients that can be treated with an 
hypothetical annual budget of c1,000,000 was assessed. RESULTS: Italian RA 
patients eligible to a ﬁ rst-line biologic therapy were estimated in 750 per year. First-
line TOC strategy induced a decrease of costs of c805,000 (−8.6% with respect to 
anti-TNFα cycling), and c1,348,000 (−3.1%) at year 1 and year 5 respectively. The 
average annual number of patients that can be treated with c1,000,000 was 75.7 at 
year1 and 78.5 at year5 under the anti-TNFα cycling strategy, while it was 82.9 at 
year 1 and 81.8 at year 5 with ﬁ rst-line TOC, with a 9.5% to 4.3% increase. CON-
CLUSIONS: The introduction of TOC among the biologic therapies available for 
Italian RA patients represents a valuable option as it is expected to induce a reduction 
in costs and a more efﬁ cient use of health care resources.
PMS19
THE INTRODUCTION OF A GERMAN ARTHROPLASTY REGISTER: COST 
SAVINGS FOR THE HEALTH CARE SYSTEM
Held R1, Gaiser S2
1Hochschule Niederrhein, Krefeld, Germany; 2Heraeus Medical GmbH, Wehrheim, Germany
OBJECTIVES: Worldwide the numbers of ﬁ rst use—implantations and revisions in 
the hip—and knee arthroplasty are rising. In many countries corresponding arthro-
plasty—registers have been introduced in order to increase the quality of such opera-
tions. Arthroplasty—registers in countries like Sweden have been improving the 
practical operations and both realizing signiﬁ cant cost savings at national level by 
reducing the revision burden results. In Germany a similar arthroplasty—register has 
not yet been introduced. METHODS: This study examines the trends in the German 
health care system which inﬂ uences the development of clinical numbers in the ﬁ eld 
of arthroplasty and makes forecasts to 2020 on the basis of the BQS—data. In a 
further step this study takes the experiences and the results of existing arthroplasty—
registers especially from Sweden into account and makes use of it for the situation in 
Germany. The aim is to identify possible cost savings when introducing such a register 
in Germany. RESULTS: The introduction of a German arthroplasty—register for hips 
seems to make an important contribution to the quality of medical care. In addition 
considerable cost savings on a national basis might be realized by reducing the revision 
burden, which exceed the cost of an arthroplasty—register by far. CONCLUSIONS: 
If the revision burden for hip arthroplasty could be reduced by one percentage point 
cost savings of about c14–23 million per year could be realized. a reduction of about 
50 per cent like in Sweden cost savings about c81–216 million per year could be 
expected. The results of this study might be a basis of discussion among 
policymakers.
PMS20
COST AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID 
ARTHRITIS IN SOUTH KOREA
Lee TJ1, Park BH1, Sohn HG1, Song YW2, Shin K2
1Seoul National University, Seoul, South Korea; 2Seoul National University Hospital, Seoul, 
South Korea
OBJECTIVES: This study aims to estimate health care cost and productivity loss and 
to measure the quality of life in patients with rheumatoid arthritis (RA), particularly 
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by its functional class (FC) in the Korean health care setting. METHODS: RA-asso-
ciated costs were estimated from a societal perspective. Health care cost was estimated 
using data from National Health Insurance (NHI) Claims Database between January 
1 and December 31, 2008. In order to estimate other health care costs, like traditional 
medicine and physiotherapy, that are not covered under the NHI and non-health care 
costs including transportation, health food and housekeeping services, face-to-face 
interviews were conducted for 202 patients with RA in a large teaching hospital in 
Seoul for 3 months starting from November 18, 2009. RA-related productivity loss 
and quality of life using EQ-5D were also estimated from the survey. Factors associ-
ated with costs as well as quality of life in RA patients were indentiﬁ ed using multiple 
regression and logistic regression. RESULTS: Total annual cost that RA patients 
incurred in 2009 was estimated to be $1.6 billion, of which almost a half was attribut-
able to productivity loss. As the function of RA patients deteriorates, annual per capita 
cost showed an increasing trend (FC I: $3534, FC II: $6057, FC III: $6722, and FC 
IV: $6856) while quality of life was lowered (FC I: 0.673, FC II: 0.502, FC III: 0.294, 
and FC IV: 0.227). Annual per capita cost increased with the deterioration of function 
(P < 0.05) and co-morbidity (P < 0.1). The quality of life was positively correlated 
with functional class (P < 0.05). CONCLUSIONS: RA patients not only incur high 
health care cost but also suffer from signiﬁ cant productivity loss and reduced quality 
of life in Korea. RA patients’ poor function is highly correlated with higher costs and 
lower quality of life.
PMS21
THE ACUTE CARE COSTS OF OSTEOPOROSIS-RELATED FRACTURES 
IN CANADA
Tarride JE1, Hopkins R1, Leslie WD2, Morin S3, Papaioannou A1, Adachi R1, Bischof M1, 
Goeree R1
1McMaster University, Hamilton, ON, Canada; 2University of Manitoba, Winnipeg, MB, 
Canada; 3McGill University, Montreal, QC, Canada
OBJECTIVES: Osteoporosis is a prevalent disease, characterized by low bone mass 
and increased fracture risk. In 1993 the economic burden of osteoporosis-related 
fractures in Canada was $1.3 billion dollars, of which $437 million was acute care. 
Our objective was to update the1993 acute care estimates for Canada for non-trau-
matic fractures. METHODS: We used national administrative databases from Cana-
dian Institute for Health Information for ﬁ scal-year ending March 31, 2008 for 
Canadians over age 50. Data sources included the Discharge Abstract Database for 
all acute care hospitalizations in Canada except Quebec; National Ambulatory Care 
Reporting System for all same day surgery, emergency visits/ambulatory services in 
hospital for Ontario. Both data sources were projected nationally using Statistics 
Canada census data. Non traumatic fractures included hip, humerus, vertebral, wrist, 
other sites (ribs/sternum, pelvis, trunk, clavicle, scapula, femur, patella, tibia/ﬁ bula), 
and multiple sites (more than 1 of the preceding). Costs were based on resource 
intensity weights for direct medical costs less physician billings. Physician fees billed 
directly to provincial plans included visits in hospital, diagnostic and surgical interven-
tions. RESULTS: Osteoporotic non-traumatic fractures were responsible for 57,404 
acute care admissions, 112,749 emergency room visits, and 3,433 same day surgeries 
in Canada in 2008. Hip fractures accounted for 50.3% of admissions, wrist fractures 
accounted for 80.8% of same day surgeries, and emergency visits mostly occurred in 
other sites (30.0%), wrist (29.7%) and hip fractures (22.9%). The cost of acute care 
was estimated at $1.2 billion with hip fractures alone costing $619 million. CONCLU-
SIONS: Osteoporosis is a chronic disease that affects a large segment of the adult 
population in Canada and increases the risk for expensive health care utilization for 
Canadians. Since 1993, the acute care cost of osteoporosis-related fractures has risen 
from $437 million to $1.2 billion dollars per year, which represents an increasing 
economic burden for Canada.
PMS22
ECONOMIC BURDEN OF OSTEOPOROSIS-RELATED FRACTURE 
HOSPITALIZATIONS IN FRANCE
Maravic M1, Vainchtock A2, Jouaneton B3, Tochon V4
1Hôpital Léopold Bellan, Paris, France; 2HEVA, LYON, France; 3HEVA, Lyon, France; 4Amgen, 
Neuilly Sur Seine, France
OBJECTIVES: To estimate the burden of post-menopausal osteoporosis-related frac-
ture hospitalizations in France for acute and rehabilitation care. METHODS: Data 
were obtained from the 2008 French Hospital National Database for women aged 
≥50 years. For acute care, criteria were established according to ICD-10 codes related 
to osteoporosis. As the rules of coding are not strictly followed in real practice, an 
additional database analysis was performed to include stays related to surgical man-
agement of hip fractures. Duplicate hospitalizations were excluded. Among women 
that were identiﬁ ed for acute care, we selected those who went in rehabilitation care 
related speciﬁ cally to osteoporosis. We assessed number of hospitalizations and 
patients, proportion of surgical management, length of stay in acute care and number 
of rehabilitation day and costs. Hospital costs were calculated according 2009 national 
hospital tariff and 2000–2001 National Scale of Costs, respectively for acute and 
rehabilitation care (2009c). RESULTS: There were 67,807 acute hospitalizations 
(64,793 patients) and 1,359,863 days for rehabilitation care (31,458 patients) associ-
ated with osteoporosis-related fractures. In acute care, a total of 80% of the hospi-
talizations were associated with the surgical management of fractures and 89% of 
them were transferred in rehabilitation care. The mean (SD) length of stay and days 
of rehabilitation were 12 ± 8 days and 43 ± 31 days, respectively. The overall cost of 
osteoporosis-related fracture hospitalizations was 415,429,993c for acute care, of 
which 6.5% was related to medical devices, and 331,755,797c for rehabilitation care. 
The mean (SD) hospital cost including medical devices, was 6127c ± 2352c per stay 
for acute care and 10,546c ± 7,869c per stay for rehabilitation care. CONCLUSIONS: 
In 2008, osteoporosis-related fracture hospitalizations were associated with a substan-
tial economic burden in France.
PMS23
BURDEN OF ILLNESS OF OSTEOPOROSIS IN AUSTRIA
Dimai H1, Redlich K2, Viernstein H3, Siebert U4, Schneider H5, Mahlich J6
1Med Uni Graz, Graz, Austria; 2Med Uni Wien, Vienna, Austria; 3Uni Wien, Vienna, Austria; 
4UMIT—Univ. of Health Sciences, Medical Informatics & Technology, Hall, Austria; 5IWI, 
Vienna, Austria; 6Austrian Economic Chamber, Vienna, Austria
OBJECTIVES: On the basis of current international prevalence, it can be estimated 
that approximately 740,000 of people in Austria over 50 years are affected by osteo-
porosis, of whom around 617,000 are women. With a fracture rate of 19.7 fractures 
per year per 10,000 inhabitants over the age of 65 years, Austria lies within the peak 
for Europe. Within the framework of a burden of illness study we examined the 
ﬁ nancial burden of osteoporosis in Austria. METHODS: We took both direct and 
indirect costs into consideration. Direct costs encompass medical costs such as 
expenses for pharmaceuticals, inpatient and outpatient medical care costs, as well as 
other medical services (e.g., occupational therapies). Non medical direct costs include 
transportation costs and medical devices (e.g., wheel chairs or crutches). Indirect costs 
refer to costs of productivity losses due to absence of work. Moreover, we included 
costs for early retirement and opportunity costs of informal care provided by family 
members. While there exist similar studies for other countries (e.g., Germany), this is 
the ﬁ rst comprehensive study for Austria. For our analysis, we combined data of both, 
ofﬁ cial statistics, expert estimates as well as unique patient surveys that are currently 
conducted in the course of an international osteoporotic fracture study in Austria. 
RESULTS: Our estimation of the total annual costs in the year 2008 imposed by 
osteoporosis in Austria is c470 million. The largest fraction of this amount is incurred 
by acute hospital treatment. Another signiﬁ cant ﬁ gure, accounting for 20% of total 
costs, is the opportunity cost of informal care. CONCLUSIONS: The ﬁ nancial burden 
of osteoporosis in Austria is substantial. Economic evaluations of preventive and 
therapeutic interventions for the speciﬁ c context of Austria are needed to inform health 
policy decision makers.
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OSTEOPOROSIS COSTS IN ITALY. INTERIM RESULTS OF THE BLOCK 
STUDY
Veronesi C1, Adami S2, Iolascon G3, Nardi A4, Pietrogrande L5, Resmini G6, Rossini M2, 
Tarantino U7, Tranquilli Leali P8, Trevisan C9, Buda S1, Intorcia M10
1CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy; 2Rheumatology Unit, 
Dpt Medicine, University of Verona, Verona, Italy; 3Dpt. Orthopedics and Rehabilitation , 
Second University of Naples, Naples, Italy; 4SOS Dpt Patologia Osteoarticolare, Azienda 
Sanitaria ULSS 18, Rovigo, Italy; 5Università degli Studi Polo San Paolo, Milano, Italy; 6Centre 
for the Study of Osteoporosis and Metabolic Bone Disease, Section of Orthopaedic and, 
Treviglio (BG), Italy; 7Division of Orthopaedics and Traumatology, Tor Vergata Foundation 
University Hospital, University of Rome Tor Vergata, Rome, Italy; 8Orthopaedic Clinic, 
Sassari University, Sassari, Italy; 9UO di Ortopedia Ospedale di Lovere, AO Bolognini, 
Lovere (BG), Italy; 10Amgen (Europe) GmbH, Zug, Switzerland
OBJECTIVES: Calculate the cost of osteoporosis in postmenopausal women after a 
fracture-related hospitalization for over a 24 months follow-up period. METHODS: 
Retrospective analysis of databases of 8 Italian Local Health Units (4 million beneﬁ -
ciaries). We included female patients (≥65 years) hospitalized for a typical osteoporotic 
fracture or osteoporosis between January 1, 2000 and December 31, 2005. Data were 
collected on hospitalizations, visits, medication and diagnostic tests in the 24 months 
after the ﬁ rst hospitalization. Over this period, treatment compliance measured as 
Medical Possession Ratio was calculated according to the proportion of days covered 
by osteoporosis-related drug treatments and classiﬁ ed as low (≤80%) and high 
(>80%). Relative unit costs for resource use were collected from DGRS, National 
Tariffs and Drugs National Formulary. RESULTS: A total of 10,158 patients were 
included (average age ± SD, 79.0 ± 7.5 years) (overall cost was c70.5 million for the 
ﬁ rst hospitalization). Of these, 98% (n = 9978) were hospitalized for a typical osteo-
porotic fracture and 180 (2%) for osteoporosis. Most were hip fractures (5189 (52%); 
76% of total costs). During 24 months follow-up, 6654 patients (66%) had resource 
utilization data (overall cost was c15.0 million; average cost per patient was c2254). 
Among all 9978 women with fracture, 21% (n = 2119) had a subsequent hospitaliza-
tion for fracture (66% were hip) and this accounted for 89% of the c15.0 million 
(11% other, diagnostic tests). Only 15% (n = 1470) of all evaluated patients received 
osteoporosis-related drug treatment within the six months following discharge and 
bisphosphonates were prescribed to 92.6% of them. Among bisphosphonate-treated 
patients, 33% (n = 459) and 66% (n = 921) displayed a high and low compliance 
level, respectively. CONCLUSIONS: In this database analysis, costs of osteoporosis 
after a ﬁ rst hospitalization for fracture were relevant and mostly due to re-hospital-
ization for a new typical osteoporotic fracture, mainly at the hip site. Exposure and 
compliance to osteoporosis treatment were suboptimal in this patient population.
